Urogen Pharma (NASDAQ:URGN) Receives “Buy” Rating from D. Boral Capital

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $33.00 target price on the stock. D. Boral Capital’s price objective suggests a potential upside of 67.03% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Urogen Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $33.29.

Urogen Pharma Trading Down 9.0%

URGN stock traded down $1.94 during mid-day trading on Monday, hitting $19.76. The stock had a trading volume of 1,015,128 shares, compared to its average volume of 717,665. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00. The firm has a market capitalization of $924.81 million, a P/E ratio of -5.72 and a beta of 1.32. The firm has a fifty day simple moving average of $21.28 and a 200 day simple moving average of $20.89.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.11. The firm had revenue of $37.84 million for the quarter, compared to analyst estimates of $39.92 million. As a group, equities analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,479 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $147,261.51. Following the sale, the general counsel owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. This represents a 12.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 7,373 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the sale, the insider owned 144,985 shares in the company, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. AQR Capital Management LLC grew its stake in Urogen Pharma by 347.5% in the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after acquiring an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after purchasing an additional 1,653 shares in the last quarter. Jane Street Group LLC grew its position in Urogen Pharma by 94.3% in the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock valued at $566,000 after purchasing an additional 24,839 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Urogen Pharma in the 2nd quarter valued at $445,000. Finally, SG Americas Securities LLC increased its stake in Urogen Pharma by 607.1% during the 2nd quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock valued at $15,742,000 after purchasing an additional 986,567 shares in the last quarter. 91.29% of the stock is owned by institutional investors.

Trending Headlines about Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Company says ZUSDURI™ commercial launch is on track; reported initial net sales of $15.8M in 2025 and permanent J‑code became effective Jan 1, 2026, which should streamline reimbursement and support broader access. UroGen Announces ZUSDURI Launch is On-Track
• Positive Sentiment: Q4 EPS beat: loss per share of ($0.54) topped consensus (-$0.65), signaling slightly better-than-expected profitability progress even as the company remains unprofitable. Urogen Pharma Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Refinancing announced with Pharmakon Advisors: new term‑loan structure (reported fixed ~8.25%) extends amortization to Q1 2030 and is described as meaningfully reducing cost of capital, which should ease near‑term liquidity pressure and be non‑dilutive. UroGen Announces Refinanced Term Loan Agreement
• Neutral Sentiment: Analysts maintain constructive views — recent consensus is an average “Moderate Buy” — which signals continued analyst support but not a unanimous upgrade catalyst. Urogen Pharma Given Average Rating of Moderate Buy
• Neutral Sentiment: Company held an earnings release and a conference call/webcast to discuss results and launch plans (management commentary will be important for near‑term guidance). Press Release
• Negative Sentiment: Revenue missed expectations: Q4 sales $37.84M versus consensus ~$39.92M, which likely fueled the intraday share weakness despite the EPS beat — investors focus on top‑line trajectory as the company commercializes new products. Revenue Miss Note

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.